Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Crohn's Disease | Research

Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn’s disease

Authors: Xiaolin Hu, Jiajia Li, Yunyun Sun, Dacheng Wu, Tiantian Zhao, Maofeng Ma, Jie Chen, Mei Wang, Sicong Hou

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

Mucosal healing has become the primary treatment target for patients with Crohn’s disease (CD). We aimed to develop a noninvasive and convenient tool to evaluate the endoscopic activity in patients with ileocolic CD.

Methods

A retrospective multicenter study including 300 CD patients (training, 210 patients; test, 90 patients) was conducted at two tertiary referral centers. Independent risk factors associated with endoscopic activity were explored, which were then combined into a comprehensive index. The predictive performance was evaluated with the area under receiver operating characteristic curve (ROC). Cohen’s Kappa was adopted to examine the consistency between each indicator and endoscopic activity.

Results

A total of 210 CD patients were recruited in the training cohort. We found that Crohn’s Disease Activity Index (CDAI), C-reactive protein (CRP) and platelet-to-lymphocyte percentage ratio (PLpR) were independently associated with endoscopic activity. Additionally, the comprehensive index generated from the above three indices achieved good discrimination and performed better than CDAI in AUC (0.849 vs. 0.769, P < 0.05). This was further well demonstrated by the external test cohort, which showed good discrimination (AUC: 0.84, 95% CI: 0.744–0.936). Intra-individual comparison revealed the comprehensive index to be superior in the prediction of endoscopic activity. In the subgroup analysis, the AUC of comprehensive index was significantly higher than CDAI especially in inflammatory phenotype (0.824 vs. 0.751, P < 0.05).

Conclusion

Combining CDAI, CRP and PLpR significantly improved the accuracy for predicting endoscopic activity in ileocolic CD, which can help better monitor an endoscopic flare.
Appendix
Available only for authorised users
Literature
1.
go back to reference Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn’s disease. The Lancet. 2017;389(10080):1741–55. Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. Crohn’s disease. The Lancet. 2017;389(10080):1741–55.
2.
go back to reference Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66.PubMed Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56–66.PubMed
3.
go back to reference Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380–9.PubMed Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35(3):380–9.PubMed
4.
go back to reference Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016;1(4):307–16.PubMed Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol. 2016;1(4):307–16.PubMed
5.
go back to reference Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, Tanyingoh D, Wei SC, Lin WC, Lin HH, et al. Population Density and Risk of Inflammatory Bowel Disease: a prospective Population-Based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107–15.PubMed Ng SC, Kaplan GG, Tang W, Banerjee R, Adigopula B, Underwood FE, Tanyingoh D, Wei SC, Lin WC, Lin HH, et al. Population Density and Risk of Inflammatory Bowel Disease: a prospective Population-Based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol. 2019;114(1):107–15.PubMed
6.
go back to reference Cho CW, You MW, Oh CH, Lee CK, Moon SK. Long-term Disease Course of Crohn’s Disease: changes in Disease Location, phenotype, activities, and predictive factors. Gut Liver. 2022;16(2):157–70.PubMed Cho CW, You MW, Oh CH, Lee CK, Moon SK. Long-term Disease Course of Crohn’s Disease: changes in Disease Location, phenotype, activities, and predictive factors. Gut Liver. 2022;16(2):157–70.PubMed
7.
go back to reference Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38.PubMed Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D’Haens G, Dotan I, Dubinsky M, Feagan B, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38.PubMed
8.
go back to reference Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83.PubMed Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel Disease (STRIDE) Initiative of the International Organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83.PubMed
9.
go back to reference Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–35.PubMed Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–35.PubMed
10.
go back to reference De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429–44.PubMed De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal healing in Crohn’s disease: a systematic review. Inflamm Bowel Dis. 2013;19(2):429–44.PubMed
11.
go back to reference Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, et al. Comparative acceptability and Perceived Clinical Utility of Monitoring Tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1425–33.PubMed Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, et al. Comparative acceptability and Perceived Clinical Utility of Monitoring Tools: a nationwide survey of patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(8):1425–33.PubMed
12.
go back to reference Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet. 2017;390(10114):2779–89. Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet. 2017;390(10114):2779–89.
13.
go back to reference Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, et al. Systematic review and external validation of Prediction Models based on symptoms and biomarkers for identifying endoscopic activity in Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(8):1704–18.PubMed Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, et al. Systematic review and external validation of Prediction Models based on symptoms and biomarkers for identifying endoscopic activity in Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(8):1704–18.PubMed
14.
go back to reference Marechal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Gueant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur Gastroenterol J. 2017;5(5):702–7. Marechal C, Aimone-Gastin I, Baumann C, Dirrenberger B, Gueant JL, Peyrin-Biroulet L. Compliance with the faecal calprotectin test in patients with inflammatory bowel disease. United Eur Gastroenterol J. 2017;5(5):702–7.
15.
go back to reference Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol. 2018;52(3):235–40.PubMed Du L, Foshaug R, Huang VW, Kroeker KI, Dieleman LA, Halloran BP, Wong K, Fedorak RN. Within-stool and within-day sample variability of fecal calprotectin in patients with inflammatory bowel disease: a prospective observational study. J Clin Gastroenterol. 2018;52(3):235–40.PubMed
16.
go back to reference Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A pilot study evaluating Novel urinary biomarkers for Crohn’s Disease. Inflamm Intest Dis. 2020;5(4):212–20.PubMedPubMedCentral Ho SS, Wall C, Gearry RB, Keenan J, Day AS. A pilot study evaluating Novel urinary biomarkers for Crohn’s Disease. Inflamm Intest Dis. 2020;5(4):212–20.PubMedPubMedCentral
17.
go back to reference Bauset C, Gisbert-Ferrandiz L, Cosin-Roger J. Metabolomics as a Promising Resource identifying potential biomarkers for inflammatory bowel disease. J Clin Med 2021, 10(4). Bauset C, Gisbert-Ferrandiz L, Cosin-Roger J. Metabolomics as a Promising Resource identifying potential biomarkers for inflammatory bowel disease. J Clin Med 2021, 10(4).
18.
go back to reference Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin. 2005;21(11):1741–54.PubMed Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin. 2005;21(11):1741–54.PubMed
19.
go back to reference Goyal H, Lippi G, Gjymishka A, John B, Chhabra R, May E. Prognostic significance of red blood cell distribution width in gastrointestinal disorders. World J Gastroenterol. 2017;23(27):4879–91.PubMedPubMedCentral Goyal H, Lippi G, Gjymishka A, John B, Chhabra R, May E. Prognostic significance of red blood cell distribution width in gastrointestinal disorders. World J Gastroenterol. 2017;23(27):4879–91.PubMedPubMedCentral
20.
go back to reference Oliveira AM, Cardoso FS, Rodrigues CG, Santos L, Martins A, de Deus JR, Reis J. Can red cell distribution width be used as a marker of Crohn’s Disease Activity? GE Port J Gastroenterol. 2016;23(1):6–12.PubMed Oliveira AM, Cardoso FS, Rodrigues CG, Santos L, Martins A, de Deus JR, Reis J. Can red cell distribution width be used as a marker of Crohn’s Disease Activity? GE Port J Gastroenterol. 2016;23(1):6–12.PubMed
21.
go back to reference Ozturk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N, Aydinli M, Kadayifci A, Kepekci Y. Could platelet indices be new biomarkers for inflammatory bowel diseases? Eur Rev Med Pharmacol Sci. 2013;17(3):334–41.PubMed Ozturk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N, Aydinli M, Kadayifci A, Kepekci Y. Could platelet indices be new biomarkers for inflammatory bowel diseases? Eur Rev Med Pharmacol Sci. 2013;17(3):334–41.PubMed
22.
go back to reference Crispino F, Grova M, Maida M, Renna S, Mocciaro F, Casa A, Rizzuto G, Tese L, Scimeca D, Di Mitri R, et al. Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes. Expert Opin Biol Ther. 2021;21(8):1133–41.PubMed Crispino F, Grova M, Maida M, Renna S, Mocciaro F, Casa A, Rizzuto G, Tese L, Scimeca D, Di Mitri R, et al. Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes. Expert Opin Biol Ther. 2021;21(8):1133–41.PubMed
23.
go back to reference Chen R, Li L, Chao K, Hong M, Cao Q, Ye L, Zhou G, Fang X, Guo H, Cao X, et al. Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn’s disease. Th Adv Gastroenterol. 2020;13:1756284820979442. Chen R, Li L, Chao K, Hong M, Cao Q, Ye L, Zhou G, Fang X, Guo H, Cao X, et al. Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn’s disease. Th Adv Gastroenterol. 2020;13:1756284820979442.
24.
go back to reference Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: a retrospective study. Med (Baltim). 2021;100(10):e24925. Zhou FS, Gao N, Sun X, Jiang XY, Chen JJ, Mao QQ, Zhong L. C-reactive protein/abumin ratio is a useful biomarker for predicting the mucosal healing in the Crohn disease: a retrospective study. Med (Baltim). 2021;100(10):e24925.
25.
go back to reference Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–12.PubMed Daperno M, D’Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004;60(4):505–12.PubMed
26.
go back to reference Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated with Better Outcomes Than partial endoscopic Healing in patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(10):2256–61.PubMed Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated with Better Outcomes Than partial endoscopic Healing in patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2020;18(10):2256–61.PubMed
27.
go back to reference Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9.PubMed Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9.PubMed
28.
go back to reference Zubin G, Peter L. Predicting Endoscopic Crohn’s Disease Activity before and after induction therapy in children: a Comprehensive Assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis. 2015;21(6):1386–91.PubMed Zubin G, Peter L. Predicting Endoscopic Crohn’s Disease Activity before and after induction therapy in children: a Comprehensive Assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis. 2015;21(6):1386–91.PubMed
29.
go back to reference Lewis JD, Rutgeerts P, Feagan BG, D’Haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, et al. Correlation of Stool frequency and Abdominal Pain Measures with simple endoscopic score for Crohn’s Disease. Inflamm Bowel Dis. 2020;26(2):304–13.PubMed Lewis JD, Rutgeerts P, Feagan BG, D’Haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, et al. Correlation of Stool frequency and Abdominal Pain Measures with simple endoscopic score for Crohn’s Disease. Inflamm Bowel Dis. 2020;26(2):304–13.PubMed
30.
go back to reference Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–9.PubMed Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–9.PubMed
31.
go back to reference af Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37. af Bjorkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Farkkila M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37.
32.
go back to reference Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-based Models Outperform patient-reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018;24(2):277–85.PubMed Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. Biomarker-based Models Outperform patient-reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018;24(2):277–85.PubMed
33.
go back to reference Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):362–73. e363.PubMed Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152(2):362–73. e363.PubMed
34.
go back to reference Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel Disease Patients: a systematic review and Meta-analysis. Am J Gastroenterol. 2015;110(6):802–19. quiz 820.PubMed Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. C-Reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel Disease Patients: a systematic review and Meta-analysis. Am J Gastroenterol. 2015;110(6):802–19. quiz 820.PubMed
35.
go back to reference Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn’s disease. Gastroenterol Hepatol. 2021;44(2):87–95.PubMed Penna FGC, Rosa RM, Pereira FH, Cunha PFS, Sousa SCS, Ferrari TCA, Cara C, Ferrari MLA. Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn’s disease. Gastroenterol Hepatol. 2021;44(2):87–95.PubMed
36.
go back to reference Yarur AJ, Quintero MA, Jain A, Czul F, Barkin JS, Abreu MT. Serum amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn’s Disease. Inflamm Bowel Dis. 2017;23(1):158–64.PubMed Yarur AJ, Quintero MA, Jain A, Czul F, Barkin JS, Abreu MT. Serum amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn’s Disease. Inflamm Bowel Dis. 2017;23(1):158–64.PubMed
37.
go back to reference Henderson P, Kennedy NA, Van Limbergen JE, Cameron FL, Satsangi J, Russell RK, Wilson DC. Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy. Inflamm Bowel Dis. 2015;21(3):596–605.PubMed Henderson P, Kennedy NA, Van Limbergen JE, Cameron FL, Satsangi J, Russell RK, Wilson DC. Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy. Inflamm Bowel Dis. 2015;21(3):596–605.PubMed
38.
go back to reference Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, Siegel CA, Bendtsen F, Burisch J. Changes in Disease Behaviour and Location in patients with Crohn’s Disease after Seven Years of Follow-Up: a danish Population-based Inception Cohort. J Crohns Colitis. 2018;12(3):265–72.PubMed Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, Siegel CA, Bendtsen F, Burisch J. Changes in Disease Behaviour and Location in patients with Crohn’s Disease after Seven Years of Follow-Up: a danish Population-based Inception Cohort. J Crohns Colitis. 2018;12(3):265–72.PubMed
39.
go back to reference Shen B, Fazio VW, Remzi FH, Bennett AE, Lavery IC, Lopez R, Brezinski A, Sherman KK, Bambrick ML, Lashner BA. Clinical features and quality of life in patients with different phenotypes of Crohn’s disease of the ileal pouch. Dis Colon Rectum. 2007;50(9):1450–9.PubMed Shen B, Fazio VW, Remzi FH, Bennett AE, Lavery IC, Lopez R, Brezinski A, Sherman KK, Bambrick ML, Lashner BA. Clinical features and quality of life in patients with different phenotypes of Crohn’s disease of the ileal pouch. Dis Colon Rectum. 2007;50(9):1450–9.PubMed
40.
go back to reference Takabayashi K, Hosoe N, Kato M, Hayashi Y, Nanki K, Fukuhara K, Mikami Y, Mizuno S, Sujino T, Mutaguchi M, et al. Significance of endoscopic deep small bowel evaluation using balloon-assisted enteroscopy for Crohn’s disease in clinical remission. J Gastroenterol. 2021;56(1):25–33.PubMed Takabayashi K, Hosoe N, Kato M, Hayashi Y, Nanki K, Fukuhara K, Mikami Y, Mizuno S, Sujino T, Mutaguchi M, et al. Significance of endoscopic deep small bowel evaluation using balloon-assisted enteroscopy for Crohn’s disease in clinical remission. J Gastroenterol. 2021;56(1):25–33.PubMed
41.
go back to reference Yang Y, Cui X, Li J, Wang H, Li Y, Chen Y, Zhang H. Clinical evaluation of vitamin D status and its relationship with disease activity and changes of intestinal immune function in patients with Crohn’s disease in the chinese population. Scand J Gastroenterol. 2021;56(1):20–9.PubMed Yang Y, Cui X, Li J, Wang H, Li Y, Chen Y, Zhang H. Clinical evaluation of vitamin D status and its relationship with disease activity and changes of intestinal immune function in patients with Crohn’s disease in the chinese population. Scand J Gastroenterol. 2021;56(1):20–9.PubMed
42.
go back to reference Chen R, Li L, Li C, Su Y, Zhang Y, Pang X, Zheng J, Zeng Z, Chen MH, Zhang S. Prealbumin and Retinol-Binding protein 4: the promising inflammatory biomarkers for identifying Endoscopic Remission in Crohn’s Disease. J Inflamm Res. 2021;14:7371–9.PubMedPubMedCentral Chen R, Li L, Li C, Su Y, Zhang Y, Pang X, Zheng J, Zeng Z, Chen MH, Zhang S. Prealbumin and Retinol-Binding protein 4: the promising inflammatory biomarkers for identifying Endoscopic Remission in Crohn’s Disease. J Inflamm Res. 2021;14:7371–9.PubMedPubMedCentral
43.
go back to reference Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble blood markers of Mucosal Healing in Inflammatory Bowel Disease: the future of noninvasive monitoring. Inflamm Bowel Dis. 2020;26(6):961–9.PubMed Nardone OM, Shivaji UN, Ferruzza V, Ghosh S, Iacucci M. Soluble blood markers of Mucosal Healing in Inflammatory Bowel Disease: the future of noninvasive monitoring. Inflamm Bowel Dis. 2020;26(6):961–9.PubMed
Metadata
Title
Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn’s disease
Authors
Xiaolin Hu
Jiajia Li
Yunyun Sun
Dacheng Wu
Tiantian Zhao
Maofeng Ma
Jie Chen
Mei Wang
Sicong Hou
Publication date
01-12-2023
Publisher
BioMed Central
Keyword
Crohn's Disease
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02968-0

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.